Episode Details
Back to Episodes
Pfizer Q1 Beats Estimates, Pipeline & Vaccines in Focus
Description
Pfizers Q1 earnings exceed expectations, driven by new launches and acquisitions. Revenue hits $14.45 billion, with adjusted EPS at $0.75. Growth in oncology and migraine meds, like Nurtec, contributes to the rise. Legal settlements boost cash flow, and cost management supports R&D investment. Analysts question vaccine rates and exclusivity losses, with Pfizer outlining pipeline strategy and Vyndamax deal. Future growth hinges on obesity and oncology trials, cost cuts, and vaccine/specialty drug market performance. Pfizer trades at $25.78, down post-earnings but with potential for post-patent rebound.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
advertise@thednn.ai
This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.
View sources & latest updates:
https://sources.thednn.ai/d79d511b69e508c2